The University of Chicago Header Logo

Connection

Mark Ferguson to Lung Neoplasms

Back to Details
This is a "connection" page, showing publications Mark Ferguson has written about Lung Neoplasms.
Mark Ferguson
Connection Strength
6.989
Lung Neoplasms
  1. The risk analysis index is an independent predictor of outcomes after lung cancer resection. PLoS One. 2024; 19(5):e0303281.
    View in: PubMed
    Score: 0.386
  2. Gender Bias in Judging Frailty and Fitness for Lung Surgery. Ann Thorac Surg. 2023 02; 115(2):356-361.
    View in: PubMed
    Score: 0.326
  3. Consensus for Thoracoscopic Lower Lobectomy: Essential Components and Targets for Simulation. Ann Thorac Surg. 2022 11; 114(5):1895-1901.
    View in: PubMed
    Score: 0.323
  4. A Morphomic Index Is an Independent Predictor of Survival After Lung Cancer Resection. Ann Thorac Surg. 2020 03; 109(3):873-878.
    View in: PubMed
    Score: 0.284
  5. Small Modifications in Technique May Yield Large Rewards After Lung Cancer Surgery. JAMA Surg. 2019 07 01; 154(7):e191014.
    View in: PubMed
    Score: 0.275
  6. Physician Gender Differences in Processing Surgical Risk Features in Videos of Standardized Patients. Ann Thorac Surg. 2019 04; 107(4):1248-1252.
    View in: PubMed
    Score: 0.265
  7. Does Race Influence Risk Assessment and Recommendations for Lung Resection? A Randomized Trial. Ann Thorac Surg. 2018 10; 106(4):1013-1017.
    View in: PubMed
    Score: 0.256
  8. The Influence of Physician and Patient Gender on Risk Assessment for Lung Cancer Resection. Ann Thorac Surg. 2017 Jul; 104(1):284-289.
    View in: PubMed
    Score: 0.236
  9. Identification of Essential Components of Thoracoscopic Lobectomy and Targets for Simulation. Ann Thorac Surg. 2017 Apr; 103(4):1322-1329.
    View in: PubMed
    Score: 0.234
  10. Video-Assisted versus Open Lobectomy in Patients with Compromised Lung Function: A Literature Review and Meta-Analysis. PLoS One. 2015; 10(7):e0124512.
    View in: PubMed
    Score: 0.209
  11. Reply: To PMID 24565405. Ann Thorac Surg. 2014 Oct; 98(4):1525-6.
    View in: PubMed
    Score: 0.198
  12. Prediction of major cardiovascular events after lung resection using a modified scoring system. Ann Thorac Surg. 2014 Apr; 97(4):1135-40.
    View in: PubMed
    Score: 0.190
  13. Association of body mass index and outcomes after major lung resection. Eur J Cardiothorac Surg. 2014 Apr; 45(4):e94-9; discussion e99.
    View in: PubMed
    Score: 0.189
  14. Lymphovascular invasion as a prognostic indicator in stage I non-small cell lung cancer: a systematic review and meta-analysis. Ann Thorac Surg. 2014 Mar; 97(3):965-71.
    View in: PubMed
    Score: 0.188
  15. Predicted postoperative lung function is associated with all-cause long-term mortality after major lung resection for cancer. Eur J Cardiothorac Surg. 2014 Apr; 45(4):660-4.
    View in: PubMed
    Score: 0.184
  16. Can we predict morbidity and mortality before an operation? Thorac Surg Clin. 2013 Aug; 23(3):287-99.
    View in: PubMed
    Score: 0.180
  17. Postoperative surveillance for non-small cell lung cancer resected with curative intent: developing a patient-centered approach. Ann Thorac Surg. 2013 Mar; 95(3):1112-21.
    View in: PubMed
    Score: 0.176
  18. Quality of life in the high-risk candidate for lung resection. Thorac Surg Clin. 2012 Nov; 22(4):497-508.
    View in: PubMed
    Score: 0.172
  19. Editorial comment: Back to the future: chest physiotherapy comes full circle. Eur J Cardiothorac Surg. 2011 Jul; 40(1):134-5.
    View in: PubMed
    Score: 0.153
  20. Quality of life and mood in older patients after major lung resection. Ann Thorac Surg. 2009 Apr; 87(4):1007-12; discussion 1012-3.
    View in: PubMed
    Score: 0.135
  21. Modeling major lung resection outcomes using classification trees and multiple imputation techniques. Eur J Cardiothorac Surg. 2008 Nov; 34(5):1085-9.
    View in: PubMed
    Score: 0.130
  22. Invited commentary. Ann Thorac Surg. 2007 Sep; 84(3):981.
    View in: PubMed
    Score: 0.121
  23. Sleeve lobectomy or pneumonectomy: optimal management strategy using decision analysis techniques. Ann Thorac Surg. 2003 Dec; 76(6):1782-8.
    View in: PubMed
    Score: 0.093
  24. Optimal management when unsuspected N2 nodal disease is identified during thoracotomy for lung cancer: cost-effectiveness analysis. J Thorac Cardiovasc Surg. 2003 Dec; 126(6):1935-42.
    View in: PubMed
    Score: 0.093
  25. A comparison of three scoring systems for predicting complications after major lung resection. Eur J Cardiothorac Surg. 2003 Jan; 23(1):35-42.
    View in: PubMed
    Score: 0.088
  26. STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2023 01; 7:e2200273.
    View in: PubMed
    Score: 0.088
  27. Lung resection surgery in Jehovah's Witness patients: a 20-year single-center experience. J Cardiothorac Surg. 2022 Oct 20; 17(1):272.
    View in: PubMed
    Score: 0.087
  28. Preoperative prediction of the risk of pulmonary complications after esophagectomy for cancer. J Thorac Cardiovasc Surg. 2002 Apr; 123(4):661-9.
    View in: PubMed
    Score: 0.083
  29. Developing a clinical and PET/CT volumetric prognostic index for risk assessment and management of NSCLC patients after initial therapy. Front Biosci (Landmark Ed). 2022 01 12; 27(1):16.
    View in: PubMed
    Score: 0.082
  30. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
    View in: PubMed
    Score: 0.081
  31. Multilevel Body Composition Analysis on Chest Computed Tomography Predicts Hospital Length of Stay and Complications After Lobectomy for Lung Cancer: A Multicenter Study. Ann Surg. 2022 05 01; 275(5):e708-e715.
    View in: PubMed
    Score: 0.074
  32. Does pneumonectomy for lung cancer adversely influence long-term survival? J Thorac Cardiovasc Surg. 2000 Mar; 119(3):440-8.
    View in: PubMed
    Score: 0.072
  33. Sex-associated differences in survival of patients undergoing resection for lung cancer. Ann Thorac Surg. 2000 Jan; 69(1):245-9; discussion 249-50.
    View in: PubMed
    Score: 0.071
  34. Diffusing capacity predicts operative mortality but not long-term survival after resection for lung cancer. J Thorac Cardiovasc Surg. 1999 Mar; 117(3):581-6; discussion 586-7.
    View in: PubMed
    Score: 0.067
  35. Effect of Endoscopic Bronchial Ultrasound on Outcomes for Stage I Non-Small-Cell Lung Cancer Patients Receiving Hypofractionated Radiotherapy. Clin Lung Cancer. 2018 03; 19(2):e227-e233.
    View in: PubMed
    Score: 0.061
  36. Coronary artery disease is associated with an increased mortality rate following video-assisted thoracoscopic lobectomy. J Thorac Cardiovasc Surg. 2017 07; 154(1):352-357.
    View in: PubMed
    Score: 0.059
  37. Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2017 Aug; 44(8):1275-1284.
    View in: PubMed
    Score: 0.059
  38. Prognostic value of quantitative PET/CT in patients with a nonsmall cell lung cancer and another primary cancer. Nucl Med Commun. 2017 Feb; 38(2):185-192.
    View in: PubMed
    Score: 0.058
  39. Limitations of PET/CT in the Detection of Occult N1 Metastasis in Clinical Stage I(T1-2aN0) Non-Small Cell Lung Cancer for Staging Prior to Stereotactic Body Radiotherapy. Technol Cancer Res Treat. 2017 02; 16(1):15-21.
    View in: PubMed
    Score: 0.056
  40. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. Oncotarget. 2016 Apr 05; 7(14):18876-86.
    View in: PubMed
    Score: 0.055
  41. Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer. Sci Rep. 2015 Jun 15; 5:10641.
    View in: PubMed
    Score: 0.052
  42. Thoracic Revised Cardiac Risk Index Is Associated With Prognosis After Resection for Stage I Lung Cancer. Ann Thorac Surg. 2015 Jul; 100(1):195-200.
    View in: PubMed
    Score: 0.052
  43. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer. J Thorac Oncol. 2013 Jul; 8(7):915-22.
    View in: PubMed
    Score: 0.045
  44. Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer. Cancer Biol Ther. 2013 Jul; 14(7):679-91.
    View in: PubMed
    Score: 0.045
  45. Synchronous primary lung cancers. Chest. 1993 Apr; 103(4 Suppl):398S-400S.
    View in: PubMed
    Score: 0.045
  46. Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One. 2012; 7(12):e50141.
    View in: PubMed
    Score: 0.044
  47. Validation of a modified scoring system for cardiovascular risk associated with major lung resection. Eur J Cardiothorac Surg. 2012 Mar; 41(3):598-602.
    View in: PubMed
    Score: 0.041
  48. Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer. Lung Cancer. 2011 Dec; 74(3):446-50.
    View in: PubMed
    Score: 0.039
  49. MET and phosphorylated MET as potential biomarkers in lung cancer. J Environ Pathol Toxicol Oncol. 2011; 30(4):341-54.
    View in: PubMed
    Score: 0.038
  50. Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol. 1990 Aug; 8(8):1402-7.
    View in: PubMed
    Score: 0.037
  51. Does induction treatment increase the risk of morbidity and mortality after pneumonectomy? A multicentre case-matched analysis. Eur J Cardiothorac Surg. 2010 Mar; 37(3):535-9.
    View in: PubMed
    Score: 0.036
  52. Lung function evaluation before surgery in lung cancer patients: how are recent advances put into practice? A survey among members of the European Society of Thoracic Surgeons (ESTS) and of the Thoracic Oncology Section of the European Respiratory Society (ERS). Interact Cardiovasc Thorac Surg. 2009 Dec; 9(6):925-31.
    View in: PubMed
    Score: 0.035
  53. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res. 2009 Sep 15; 15(18):5714-23.
    View in: PubMed
    Score: 0.035
  54. MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance. J Environ Pathol Toxicol Oncol. 2009; 28(2):89-98.
    View in: PubMed
    Score: 0.033
  55. Lymphatic vessel density is not associated with lymph node metastasis in non-small cell lung carcinoma. Arch Pathol Lab Med. 2008 Dec; 132(12):1882-8.
    View in: PubMed
    Score: 0.033
  56. Diffusing capacity predicts morbidity after lung resection in patients without obstructive lung disease. Ann Thorac Surg. 2008 Apr; 85(4):1158-64; discussion 1164-5.
    View in: PubMed
    Score: 0.032
  57. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer. J Thorac Oncol. 2008 Jan; 3(1):59-67.
    View in: PubMed
    Score: 0.031
  58. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res. 2008 Jan 01; 68(1):132-42.
    View in: PubMed
    Score: 0.031
  59. Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers. Am J Clin Oncol. 2007 Jun; 30(3):258-63.
    View in: PubMed
    Score: 0.030
  60. Consensus for Thoracoscopic Left Upper Lobectomy-Essential Components and Targets for Simulation. Ann Thorac Surg. 2021 08; 112(2):436-442.
    View in: PubMed
    Score: 0.019
  61. Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: a Phase I study. Semin Oncol. 1996 Apr; 23(2 Suppl 5):48-52.
    View in: PubMed
    Score: 0.014
  62. Optimizing selection of patients for major lung resection. J Thorac Cardiovasc Surg. 1995 Feb; 109(2):275-81; discussion 281-3.
    View in: PubMed
    Score: 0.013
  63. Concomitant chemoradiotherapy for non-small cell lung cancer. Lung Cancer. 1994 Mar; 10 Suppl 1:S253-61.
    View in: PubMed
    Score: 0.012
  64. Dedifferentiated chordoma. Response to aggressive chemotherapy in two cases. Cancer. 1993 Aug 01; 72(3):714-8.
    View in: PubMed
    Score: 0.011
  65. The impact on survival by adjuvant chemotherapy and radiation therapy in stage II non-small-cell lung cancer. Am J Clin Oncol. 1992 Oct; 15(5):405-11.
    View in: PubMed
    Score: 0.011
  66. 5-Fluorouracil with oral leucovorin and hydroxyurea and concomitant radiotherapy for stage III non-small cell lung cancer. Cancer. 1990 Aug 01; 66(3):437-42.
    View in: PubMed
    Score: 0.009
  67. Efficacy of computed tomography of the thorax and upper abdomen and whole-body gallium scintigraphy for staging of lung cancer. Cancer. 1989 Oct 01; 64(7):1404-8.
    View in: PubMed
    Score: 0.009
  68. Neoadjuvant vindesine, etoposide, and cisplatin for locally advanced non-small cell lung cancer. Final report of a phase 2 study. Chest. 1989 Jul; 96(1):110-3.
    View in: PubMed
    Score: 0.009
  69. Adenosquamous lung carcinoma: clinical characteristics, treatment, and prognosis. Ann Thorac Surg. 1987 Nov; 44(5):462-6.
    View in: PubMed
    Score: 0.008
  70. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest. Cancer Chemother Pharmacol. 1995; 35(4):304-12.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.